Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biofilgragen vs Neupogen in Healthy Volunteers
NCT07877467Phase 1Not yet recruiting
- Sponsor
- BioGeneric Pharma
- Start
- Dec 2026
- Primary completion
- Apr 2027
01
Overview
Phase 1, randomised, double-blind trial of filgrastim in neutropenia (2 arms), sponsored by BioGeneric Pharma. Primary endpoints: Maximum observed serum filgrastim concentration at 24 hours, Time to reach maximum observed serum filgrastim concentration at 24 hours and 2 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
filgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT07877467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07877467.